TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38281023

Group type: EXPERIMENTAL
Intervention: Behavioural intervention bundles (including theatre, posters, discussions, etc.) aimed at rationalising Watch antibiotic use and improving hygiene and sanitation practices.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Long-term impact on AMR estimated by modelling changes in resistant Enterobacteriaceae carriage from repeated household surveys.
Number of subjects: 11
Study: 38281089

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 3082

Group type: EXPERIMENTAL
Intervention: Vitamin-K antagonists (VKAs)
Number of subjects: 3082

Group type: COMPARATOR
Intervention: All scores tested
Number of subjects: 3082
Study: 38281295

Group type: EXPERIMENTAL
Intervention: Rivoceranib 700 mg once daily
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Rivoceranib 700 mg once daily in ≥4th-line therapy
Number of subjects: 460
Study: 38281309

Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg as monotherapy or in combination with a phosphodiesterase 5 inhibitor
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg
Number of subjects: 45
Study: 38281499

Group type: EXPERIMENTAL
Intervention: Vi polysaccharide conjugated to tetanus toxoid vaccine (Vi-TT)
Number of subjects: 28130

Group type: COMPARATOR
Intervention: Meningococcal capsular group A conjugate (MenA) vaccine
Number of subjects: 28130
Study: 38281569

Group type: EXPERIMENTAL
Intervention: Contrast Sensitivity (CS)
Number of subjects: 1159
Study: 38281579

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) with computerized lexical-semantic treatment (15 sessions, 2-3 times/week, 45 minutes each, tDCS for first 20 minutes)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS) with computerized lexical-semantic treatment (15 sessions, 2-3 times/week, 45 minutes each, tDCS for first 20 minutes)
Number of subjects: 43
Study: 38281619

Group type: EXPERIMENTAL
Intervention: MTA (PDTM MTA WHITE)+SSC
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: MTA+GI (bulk fill glass ionomer with glass hybrid technology GC EQUIA Forte® HT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: BC RRM-F+GI
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: BC RRM-F+SCC
Number of subjects: 64

Group type: COMPARATOR
Intervention: GI
Number of subjects: 64

Group type: COMPARATOR
Intervention: SCC
Number of subjects: 64
Study: 38281914

Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor-based immunotherapy in MSI-H patients
Number of subjects: 887

Group type: COMPARATOR
Intervention: MSI-H status
Number of subjects: 887
Study: 38281994

Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 694
Study: 38282003

Group type: EXPERIMENTAL
Intervention: QL1706 plus chemotherapy (with or without bevacizumab)
Number of subjects: 91
Study: 38282192

Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (PTAH)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 38282258

Group type: EXPERIMENTAL
Intervention: reduction counseling + nicotine mini-lozenges + encouragement to quit starting 1 month post-randomization (preparation)
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: recycling (immediate encouragement to quit)
Number of subjects: 1154

Group type: COMPARATOR
Intervention: quitline referral (control)
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: skill training (on vs off)
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: supportive counseling (on vs off)
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: preparation (reduction counseling)
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: recycling
Number of subjects: 1154
Study: 38282387

Group type: EXPERIMENTAL
Intervention: Weight loss ≥2 kg
Number of subjects: 21028

Group type: EXPERIMENTAL
Intervention: Weight gain ≥5 kg
Number of subjects: 21028

Group type: EXPERIMENTAL
Intervention: Overweight to normal weight
Number of subjects: 21028

Group type: EXPERIMENTAL
Intervention: Becoming underweight
Number of subjects: 21028

Group type: EXPERIMENTAL
Intervention: Stable overweight
Number of subjects: 21028
Study: 38282503

Group type: EXPERIMENTAL
Intervention: 10 mL 0.25% bupivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: 20 mL 0.25% bupivacaine
Number of subjects: 80
Study: 38282695

Group type: EXPERIMENTAL
Intervention: Intensive meditation training (10-day Vipassana meditation retreat, 100 hr of sitting meditation)
Number of subjects: 58
Study: 38283151

Group type: EXPERIMENTAL
Intervention: Selective screening using LC-MS/MS method
Number of subjects: 750
Study: 38283244

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation with reduced-intensity conditioning and protracted immune suppression
Number of subjects: 2
Study: 38283394

Group type: EXPERIMENTAL
Intervention: Perioperative intravenous tranexamic acid (TXA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38283573

Group type: EXPERIMENTAL
Intervention: Portico valve (size 23, 25, 27, or 29 mm) using first-generation delivery system (DS)
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Portico valve (size 23, 25, 27, or 29 mm) using second-generation (FlexNav) DS
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Portico valve (size 23, 25, 27, or 29 mm)
Number of subjects: 1001
Study: 38283689

Group type: EXPERIMENTAL
Intervention: Intramuscular ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam (control)
Number of subjects: 0
Study: 38284238

Group type: EXPERIMENTAL
Intervention: Conduction system pacing (CSP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Right ventricular apical pacing (RVAP)
Number of subjects: 75
Study: 38284286

Group type: EXPERIMENTAL
Intervention: 90 W power setting
Number of subjects: 46

Group type: COMPARATOR
Intervention: 50 W power setting
Number of subjects: 46
Study: 38284396

Group type: EXPERIMENTAL
Intervention: Gentle parental touch intervention during painful procedures
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Participation in the Petal trial
Number of subjects: 106
Study: 38284415

Group type: EXPERIMENTAL
Intervention: Patient decision aids
Number of subjects: 107698
Study: 38284768

Group type: EXPERIMENTAL
Intervention: MINS (Myocardial Injury after Noncardiac Surgery) defined as TnI level >59 ng/L
Number of subjects: 341

Group type: COMPARATOR
Intervention: Patients without MINS
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Dynamic TnI changes
Number of subjects: 341
Study: 38284925

Group type: EXPERIMENTAL
Intervention: Telehealth-based contingency management intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38285028

Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transversus abdominis plane (TAP) block
Number of subjects: 50
Study: 38285051

Group type: EXPERIMENTAL
Intervention: Early postoperative-AKI
Number of subjects: 9510

Group type: EXPERIMENTAL
Intervention: Severity of early postoperative-AKI
Number of subjects: 9510

Group type: EXPERIMENTAL
Intervention: Duration of early postoperative-AKI
Number of subjects: 9510

Group type: EXPERIMENTAL
Intervention: Patients with pre-existing CKD
Number of subjects: 9510

Group type: EXPERIMENTAL
Intervention: Patients with CKD and early AKI
Number of subjects: 9510
Study: 38285168

Group type: EXPERIMENTAL
Intervention: Short stitch with a longterm resorbable, elastic suture (poly-4-hydroxybutyrate, [p-4OHB]) aiming at a 6:1 SL/WL-ratio
Number of subjects: 351
Study: 38285175

Group type: EXPERIMENTAL
Intervention: Respiratory sinus arrhythmia (RSA) reactivity and resting RSA as physiological markers
Number of subjects: 0
Study: 38285235

Group type: EXPERIMENTAL
Intervention: Trial 58741 (1971-1978)
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: Trial 58831/2
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: Trial 58881
Number of subjects: 890
Study: 38285244

Group type: EXPERIMENTAL
Intervention: Pharmacological ascorbate (intravenous delivery reaching plasma concentrations ≈ 20 mM)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Transferrin receptor expression
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Quantitative Susceptibility Mapping (QSM) measures
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Systemic iron metabolic markers
Number of subjects: 55
Study: 38285245

Group type: EXPERIMENTAL
Intervention: Cognitive reserve, depressive symptoms, obesity, and change in employment status
Number of subjects: 426
Study: 38285445

Group type: EXPERIMENTAL
Intervention: 2-dose nonavalent HPV vaccine administered 6 months apart
Number of subjects: 225

Group type: COMPARATOR
Intervention: 3-dose HPV vaccine regimen administered to historical controls
Number of subjects: 225
Study: 38285447

Group type: EXPERIMENTAL
Intervention: Nighttime Bracing (NB)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Scoliosis-Specific Exercise (SSE)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Physical Activity (PA) - Control
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 135
Study: 38285446

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (20 mg, followed by 10 mg every 5 minutes)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Intravenous morphine sulfate (2 or 3 mg every 5 minutes)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Number of subjects: 251
Study: 38285475

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38285502

Group type: EXPERIMENTAL
Intervention: Remote diabetes self-management education (DSME) program including live video education classes, individualized physical activity prescription and counseling, and continuous glucose and wearable physical activity monitoring.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Remote DSME program with Fitbit Inspire 2 for physical activity assessment and estimated glycated hemoglobin (HbA1c) monitoring.
Number of subjects: 10
Study: 38285565

Group type: EXPERIMENTAL
Intervention: Committing to Choose Wisely behavioral economic intervention
Number of subjects: 8030

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 8030
Study: 38286086

Group type: EXPERIMENTAL
Intervention: CatboostClassifier
Number of subjects: 11201

Group type: EXPERIMENTAL
Intervention: RandomForestClassifier
Number of subjects: 11201

Group type: COMPARATOR
Intervention: Logistic Regression
Number of subjects: 11201

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 11201
Study: 38286177

Group type: EXPERIMENTAL
Intervention: High-dose quadrivalent influenza vaccine (QIV-HD)
Number of subjects: 12477
Study: 38286223

Group type: EXPERIMENTAL
Intervention: GetActive-Fitbit mind-body activity program
Number of subjects: 87

Group type: COMPARATOR
Intervention: Healthy Living for Pain (educational comparison)
Number of subjects: 87
Study: 38286244

Group type: EXPERIMENTAL
Intervention: Rotational activations
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Focal activations
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proportion of left atrium occupied by LVZs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Healthy atrium with ≤15% LVZs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rotational activations in LVZs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Presence of LVZ within 12 mm of focal activation
Number of subjects: 40
Study: 38286482

Group type: EXPERIMENTAL
Intervention: Reteplase (18 mg + 18 mg)
Number of subjects: 1412

Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg)
Number of subjects: 1412
Study: 38286484

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg tenecteplase
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 0.32 mg/kg tenecteplase
Number of subjects: 86
Study: 38286485

Group type: EXPERIMENTAL
Intervention: Ticagrelor-aspirin
Number of subjects: 6412

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 6412
Study: 38286618

Group type: EXPERIMENTAL
Intervention: AtoOxy (80/5 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: AtoOxy-plus-acetazolamide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 38286619

Group type: EXPERIMENTAL
Intervention: Specialist-led COPD care
Number of subjects: 1242

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1242
Study: 38286683

Group type: EXPERIMENTAL
Intervention: Daily cyclic enteral nutrition administered over 10 hours
Number of subjects: 318

Group type: COMPARATOR
Intervention: Standard continuous enteral nutrition
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Daily cyclic enteral nutrition
Number of subjects: 318
Study: 38286685

Group type: EXPERIMENTAL
Intervention: Trauma-focused art therapy (TFAT) intervention for 10 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline period (control)
Number of subjects: 30
Study: 38286686

Group type: EXPERIMENTAL
Intervention: Cryotherapy plus compression therapy for 6 weeks after discharge from hospital
Number of subjects: 208

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 208
Study: 38286689

Group type: EXPERIMENTAL
Intervention: Home-based bimodal lifestyle programme
Number of subjects: 0
Study: 38286691

Group type: EXPERIMENTAL
Intervention: Cooling treatment for fever control within the first 48 hours of septic shock
Number of subjects: 820

Group type: COMPARATOR
Intervention: No cooling treatment for fever control within the first 48 hours of septic shock
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Cooling treatment for fever control
Number of subjects: 820

Group type: COMPARATOR
Intervention: No cooling treatment for fever control
Number of subjects: 820
Study: 38286705

Group type: EXPERIMENTAL
Intervention: Eye-Movement Desensitisation and Reprocessing (EMDR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 38286704

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 6004
Study: 38286736

Group type: EXPERIMENTAL
Intervention: Iliopsoas plane block (10 mL 0.75% ropivacaine with 1:200 000 epinephrine)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham block (10 mL normal saline)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study: 38286884

Group type: EXPERIMENTAL
Intervention: Adjuvant Therapy (AT)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX as Adjuvant Therapy
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Adjuvant Therapy (AT) Delay
Number of subjects: 317
Study: 38286916

Group type: EXPERIMENTAL
Intervention: Educational program for sleep enhancement (two sessions)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Routine practices of the hospital (control group)
Number of subjects: 181
Study: 38286961

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 380
Study: 38287068

Group type: EXPERIMENTAL
Intervention: ChulaCov19 50 µg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 38287179

Group type: EXPERIMENTAL
Intervention: Gartisertib (250 mg QD) in cohort A2
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Gartisertib + Carboplatin in cohort B1
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Gartisertib (general)
Number of subjects: 97
Study: 38287253

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) prevalence defined as serum ferritin < 100 µg/L and/or transferrin saturation coefficient (TSAT) < 20%
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Presence of more than three comorbidities
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: CRP ≥ 12 mg/L
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Treatment that may influence ID/anemia
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: SPPB scores
Number of subjects: 888
Study: 38287286

Group type: EXPERIMENTAL
Intervention: Identified source of infection
Number of subjects: 584846

Group type: EXPERIMENTAL
Intervention: Suspected source of infection
Number of subjects: 584846

Group type: EXPERIMENTAL
Intervention: Household members as source of infection
Number of subjects: 584846

Group type: EXPERIMENTAL
Intervention: Extended family as source of infection
Number of subjects: 584846

Group type: EXPERIMENTAL
Intervention: Work colleagues as source of infection
Number of subjects: 584846

Group type: EXPERIMENTAL
Intervention: Friends as source of infection
Number of subjects: 584846

Group type: EXPERIMENTAL
Intervention: Multiple/other sources as infection source
Number of subjects: 584846

Group type: EXPERIMENTAL
Intervention: Indoor settings for transmission events
Number of subjects: 584846

Group type: EXPERIMENTAL
Intervention: Prolonged encounters for transmission events
Number of subjects: 584846

Group type: EXPERIMENTAL
Intervention: Symptomatic source case for transmission events
Number of subjects: 584846

Group type: EXPERIMENTAL
Intervention: Mask usage during transmission events
Number of subjects: 584846

Group type: EXPERIMENTAL
Intervention: Factors associated with not knowing the source of infection
Number of subjects: 584846
Study: 38287303

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 168

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 168
Study: 38287335

Group type: EXPERIMENTAL
Intervention: ENABLE-SG (telehealth model)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Delayed ENABLE-SG (control)
Number of subjects: 300
Study: 38287346

Group type: EXPERIMENTAL
Intervention: Radionuclide therapy (RNT) targeted against prostate-specific membrane antigen (PSMA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 38287349

Group type: EXPERIMENTAL
Intervention: Myo-inositol, probiotics, and additional micronutrients
Number of subjects: 576

Group type: COMPARATOR
Intervention: Standard micronutrient supplement
Number of subjects: 576
Study: 38287417

Group type: EXPERIMENTAL
Intervention: Active manual soft tissue mobilisation of the lumbar spine (n=11)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control intervention: light touch over the thoracic region with deep breathing exercises (n=13)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Outcome assessors for active group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Outcome assessors for control group
Number of subjects: 24
Study: 38287424

Group type: EXPERIMENTAL
Intervention: Follicular phase-based training
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Luteal phase-based training
Number of subjects: 120

Group type: COMPARATOR
Intervention: Regular training during menstrual cycle
Number of subjects: 120
Study: 38287431

Group type: EXPERIMENTAL
Intervention: Exercise intervention (6-month duration)
Number of subjects: 27
Study: 38287611

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg bodyweight intravenously followed by weekly subcutaneous injections of 162 mg) after 500 mg methylprednisolone intravenously for 3 days.
Number of subjects: 18
Study: 38287700

Group type: EXPERIMENTAL
Intervention: Adding Calcium (Ca)
Number of subjects: 0
Study: 38287923

Group type: EXPERIMENTAL
Intervention: Stepped collaborative care intervention including care management, cognitive behavioral therapy elements, and psychopharmacology addressing PTSD symptoms.
Number of subjects: 350

Group type: COMPARATOR
Intervention: Enhanced usual care control
Number of subjects: 350
Study: 38288052

Group type: EXPERIMENTAL
Intervention: Estimated risk score for in-hospital mortality
Number of subjects: 2229

Group type: EXPERIMENTAL
Intervention: Estimated risk score for composite outcome
Number of subjects: 2229

Group type: EXPERIMENTAL
Intervention: Estimated risk score for late mortality
Number of subjects: 2229

Group type: EXPERIMENTAL
Intervention: Estimated risk score predictive of in-hospital mortality
Number of subjects: 2229

Group type: EXPERIMENTAL
Intervention: Estimated risk score predictive of composite outcome
Number of subjects: 2229

Group type: EXPERIMENTAL
Intervention: Estimated risk score predictive of late mortality excluding hospital deaths
Number of subjects: 2229
Study: 38288082

Group type: EXPERIMENTAL
Intervention: Adjudication algorithm for respiratory-related hospitalisation
Number of subjects: 0
Study: 38288117

Group type: EXPERIMENTAL
Intervention: 2-cycle induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy (cCRT) and consolidation toripalimab
Number of subjects: 50

Group type: COMPARATOR
Intervention: 2-cycle induction chemotherapy followed by concurrent chemoradiotherapy (cCRT) and consolidation toripalimab
Number of subjects: 50
Study: 38288393

Group type: EXPERIMENTAL
Intervention: Digital bracket positioning using 3D Maestro® software
Number of subjects: 30

Group type: COMPARATOR
Intervention: Manual bracket positioning using Ray Set® device
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CAD/CAM jigs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3D-printed indirect bonding trays (IBT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Double-layer vacuum-formed thermoplastic IBT
Number of subjects: 30
Study: 38288731

Group type: EXPERIMENTAL
Intervention: Serum urate responders (achieved serum urate < 6 mg/dL)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Serum urate non-responders (did not achieve serum urate < 6 mg/dL)
Number of subjects: 588

Group type: EXPERIMENTAL
Intervention: Serum urate responders
Number of subjects: 588

Group type: COMPARATOR
Intervention: Serum urate non-responders
Number of subjects: 588
Study: 38288741

Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of 1 × 10^6 allogeneic bone marrow-derived mesenchymal stromal cells
Number of subjects: 20
Study: 38288802

Group type: EXPERIMENTAL
Intervention: Keytruda (pembrolizumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imfinzi (durvalumab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38288862

Group type: EXPERIMENTAL
Intervention: Doublet regimen (cobimetinib 60 mg daily for days 1-21 + niraparib 200 mg daily for days 1-28)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Triplet regimen (cobimetinib 60 mg daily for days 1-21 + niraparib 200 mg daily for days 1-28 + atezolizumab 840 mg on days 1 and 15)
Number of subjects: 74
Study: 38288892

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Ixekizumab Q2W
Number of subjects: 266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266